Please assess the completion status of the following clinical trial:

Trial Title: Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~* Must have received prior high-dose conditioning chemotherapy followed by autologous stem cell transplant (ASCT) as a part of salvage therapy for cHL (cohort A, B \& C - enrollment closed)~* Participants may be Brentuximab vedotin- naïve, or may have had prior Brentuximab vedotin treatment (cohort A, B \& C - enrollment closed)~* Newly diagnosed and previously untreated classical Hodgkin Lymphoma (cohort D)~Exclusion Criteria:~* Known central nervous system lymphoma~* Participants with nodular lymphocyte-predominant Hodgkin Lymphoma~* Prior allogeneic stem cell transplantation (SCT)~* Chest radiation ≤ 24 weeks prior to first dose~* Carmustine ≥ 600 mg/m² received as part of the pre-transplant conditioning regimen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab (Cohort A, B, C and D) (Type: EXPERIMENTAL): Cohort (A, B, C): Nivolumab: Specified dose on specified days~Cohort (D): Nivolumab: Specified dose on specified days + Doxorubicin: Specified dose on specified days + Vinblastine: Specified dose on specified days + Dacarbazine: Specified dose on specified days

Based on this trial design, predict the completion outcome and termination type (if applicable).